CoChat

Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder

Lozupone, Madia, La Montagna, Maddalena, D’Urso, Francesca, Piccininni, Carla, Sardone, Rodolfo, Dibello, Vittorio, Giannelli, Gianluigi, Solfrizzi, Vincenzo, Greco, Antonio, Daniele, Antonio, Quaranta, Nicola, Seripa, Davide, Bellomo, Antonello, Logroscino, Giancarlo, Panza, Francesco · 2018 · Expert Opinion on Pharmacotherapy
Cited by 50

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondemented subjects. AREAS COVERED: The following article looks at the selective serotonin reuptake inhibitor sertraline, which is one of the most frequently studied antidepressant medications in randomized controlled trials (RCTs). It also discusses many other pharmacological approaches that have proven to be inadequate (antipsychotics, acetylcholinesterase inhibitors, anticonvulsants, hormone replacement therapy) and new drug classes (mainly affecting glutamate transmission) that are being studied for treating depression in AD. It also gives discussion to the phase II RCT on the alternative drug S47445 and the potential effect on cognition of the multimodal antidepressant vortioxetine in older depressed patients. Finally, it discusses the N-methyl-D-aspartate antagonist ketamine. EXPERT OPINION: The present RCT methodologies are too disparate to draw firm conclusions. Future studies are required to identify effective and multimodal pharmacological treatments that efficiently treat depression in AD. Genotyping may boost antidepressant treatment success.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14656566.2018.1471136

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 50

Metadata

Authors
Lozupone, M., La Montagna, M., D’Urso, F., Piccininni, C., Sardone, R., Dibello, V., Giannelli, G., Solfrizzi, V., Greco, A., Daniele, A., Quaranta, N., Seripa, D., Bellomo, A., Logroscino, G., & Panza, F.
Venue
Expert Opinion on Pharmacotherapy
Published
2018-05-04
Volume
19
Issue
8
Pages
823-842
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2800288813
Cited by
50
References
38
FWCI
2.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder. https://app.cochat.ai/papers/10.1080/14656566.2018.1471136
The paper
Lozupone, M., La Montagna, M., D’Urso, F., Piccininni, C., Sardone, R., Dibello, V., Giannelli, G., Solfrizzi, V., Greco, A., Daniele, A., Quaranta, N., Seripa, D., Bellomo, A., Logroscino, G., & Panza, F. (2018). Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2018.1471136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.